NTM 1634

Drug Profile

NTM 1634

Alternative Names: BoNT C/D; NTM-1634

Latest Information Update: 11 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard Medical School; University of California at San Francisco
  • Developer Nanotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Botulinum toxin inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Botulism; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Severe acute respiratory syndrome

Most Recent Events

  • 20 Mar 2017 Phase-I clinical trials in Botulism (In volunteers) in USA (IV)
  • 20 Mar 2017 Phase-I clinical trials in Influenza-A virus H1N1 subtype (In volunteers) in USA (IV)
  • 20 Mar 2017 Phase-I clinical trials in Influenza-A virus H5N1 subtype (In volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top